Studies suggest that a single intra-discal injection of 6 million Mesenchymal Precursor Cells (MPCs) resulted in meaningful improvements in chronic low back pain (CLBP) and function that were durable for at least 36 months.
Mesoblast announced the results from a randomized, placebo-controlled 100-patient Phase II trial of its proprietary allogeneic MPCs in the treatment of CLBP due to intervertebral disc degeneration. The trial compared MPCs against saline or hyaluronic acid placebo.
The 36-month Phase II trial results support the ongoing 360-patient Phase III trial of product candidate MPC-06-ID for CLBP by reinforcing the rationale for MPC dose selection, use of saline control and the trial’s primary endpoint composite over 24 months. If similar clinical durability is seen in the Phase III program, it is anticipated such data will translate into meaningful health economic benefits including increased productivity that may support attractive product reimbursement.
Studies suggest that a single intra-discal injection of 6 million Mesenchymal Precursor Cells (MPCs) resulted in meaningful improvements in chronic low back pain (CLBP) and function that were durable for at least 36 months.
Mesoblast announced the results from a randomized, placebo-controlled 100-patient Phase II trial of its...
Studies suggest that a single intra-discal injection of 6 million Mesenchymal Precursor Cells (MPCs) resulted in meaningful improvements in chronic low back pain (CLBP) and function that were durable for at least 36 months.
Mesoblast announced the results from a randomized, placebo-controlled 100-patient Phase II trial of its proprietary allogeneic MPCs in the treatment of CLBP due to intervertebral disc degeneration. The trial compared MPCs against saline or hyaluronic acid placebo.
The 36-month Phase II trial results support the ongoing 360-patient Phase III trial of product candidate MPC-06-ID for CLBP by reinforcing the rationale for MPC dose selection, use of saline control and the trial’s primary endpoint composite over 24 months. If similar clinical durability is seen in the Phase III program, it is anticipated such data will translate into meaningful health economic benefits including increased productivity that may support attractive product reimbursement.
Copy to clipboard 
